DEA Pushes Back on Cannabis Rescheduling Delays: What It Means for Schedule III and Cannabis M&A
Cannabis rescheduling has hit another procedural delay, but the Drug Enforcement Administration (DEA) is pushing back against efforts to prolong the process.
Following months of hearings over whether marijuana should move from Schedule I to Schedule III under federal law, opponents of rescheduling have requested additional briefing, testimony and document discovery.
The DEA has taken a different position. While leaving it to the administrative law judge to decide whether a newly released federal report belongs in the hearing record, the agency argues that additional briefing is unnecessary.
For cannabis business owners, investors and prospective acquirers, this is more than a regulatory headline.
Schedule III could materially affect cannabis business economics, federal tax exposure, access to capital and ultimately M&A valuations. But the timing and scope of those benefits remain critical.
Here's what happened, what's already changed and what the industry should watch next.
Why the Delay?
The DEA has been conducting a formal administrative hearing to determine whether marijuana should be transferred from Schedule I to Schedule III of the Controlled Substances Act.
The hearing concluded July 15, 2026, after 11 days of proceedings. Participating parties subsequently submitted their final arguments, and DEA Chief Administrative Law Judge Derek C. Julius was expected to issue a recommendation.
Then a new report complicated the process.
In September, the U.S. Government Accountability Office (GAO) released findings identifying gaps in how the DEA and Food and Drug Administration (FDA) document certain drug-scheduling procedures.
Opponents of rescheduling argued that the report warranted additional review before the judge issued his recommendation.
On September 29, Judge Julius paused the proceedings to consider their request.
The DEA responded on October 9.
Its position was straightforward: the judge may decide whether to include the GAO report, but the report does not establish that the underlying scientific analysis supporting Schedule III was defective. The DEA therefore opposed additional briefing.
Opponents have also sought new testimony and document discovery, raising the possibility of a longer delay.
The important distinction: The DEA is not withdrawing its support for Schedule III. It is opposing additional procedural steps that it considers unnecessary.
Sources: Cannabis Business Times | Marijuana Moment
Cannabis Rescheduling Timeline: How We Got Here
Sources: GAO Report | DEA Regulatory Actions
Has Marijuana Already Been Rescheduled to Schedule III?
This is an important distinction that has been lost in some discussions about federal cannabis reform.
On April 28, 2026, the Department of Justice issued a final rule placing FDA-approved products containing marijuana and qualifying state-regulated medical marijuana products in Schedule III.
However, the broader proposal to transfer marijuana generally from Schedule I to Schedule III remains under administrative review.
The April action also preserves federal controls and includes additional regulatory requirements. It should not be interpreted as automatic federal authorization for every state-licensed cannabis operation.
For California cannabis businesses, the practical consequences depend on the specific products, licenses, activities and applicable federal requirements.
Schedule III is not the same as federal legalization.
Nor does it automatically authorize interstate cannabis commerce, eliminate California licensing requirements or guarantee conventional financing.
Why Is the GAO Report Delaying the Hearing?
The GAO report examined federal drug-scheduling procedures and identified shortcomings in the agencies' written policies and documentation.
Opponents of marijuana rescheduling argue that these findings raise questions about the process used to evaluate marijuana's medical use and appropriate federal classification.
The DEA disagrees with that interpretation.
According to the agency, the report concerns gaps in documenting procedures—not demonstrated defects in the underlying scientific analysis.
That distinction matters because the federal rescheduling decision turns on statutory requirements, including marijuana's currently accepted medical use and its potential for abuse and dependence.
The GAO report does not itself determine marijuana's appropriate schedule.
Judge Julius must now decide whether to admit the report and whether any further proceedings are justified.
The outcome could affect the timetable, but the procedural stay does not by itself reverse the government's proposed Schedule III classification.
Sources: GAO | Marijuana Moment
Why Schedule III Matters for Cannabis Business Valuations
For cannabis operators, the largest potential economic impact of broader rescheduling may be federal taxation.
1. Section 280E and Cannabis Taxes
Internal Revenue Code Section 280E generally prevents businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses.
That has created a significant tax burden for many state-legal cannabis operators.
If broader rescheduling places qualifying marijuana activities in Schedule III, Section 280E would no longer apply to those activities solely because marijuana is classified in Schedule I or II.
That could improve after-tax cash flow.
However, the effective date, scope of coverage and treatment of particular operations require careful legal and tax analysis. The April 2026 medical-product rule should not be treated as a blanket resolution of Section 280E for the entire cannabis industry.
For owners and buyers, potential tax savings should be evaluated rather than automatically included in current earnings.
2. Cannabis EBITDA and Acquisition Valuations
Cannabis businesses are frequently evaluated using revenue, gross profit, EBITDA, seller's discretionary earnings and other operating metrics.
A reduction in federal tax exposure could increase after-tax cash flow and the capital available for debt service, reinvestment and acquisitions.
But there's an important financial distinction:
Lower income taxes do not automatically increase EBITDA.
EBITDA excludes income taxes by definition. The potential benefit is principally to after-tax cash flow and overall business economics, which may influence valuation multiples, financing capacity and buyer demand.
A sophisticated buyer should distinguish historical performance from potential future regulatory benefits.
3. Access to Capital and Cannabis Financing
Schedule III could improve the industry's long-term investment outlook by reducing some regulatory and tax-related friction.
That may eventually support greater lender interest, strategic acquisitions and recapitalizations.
But rescheduling alone does not guarantee access to traditional bank financing, eliminate federal compliance obligations or resolve every institutional investment restriction.
Capital markets respond to the actual regulatory framework—not simply the announcement of a proposed change.
What Does This Mean for Cannabis M&A in California?
We believe the implications for cannabis mergers and acquisitions are potentially substantial.
California remains a highly fragmented cannabis market, with businesses operating across retail, cultivation, manufacturing, distribution and branded products.
Many operators continue to face pressure from taxes, financing costs, competition, operating expenses and legacy real estate obligations.
A meaningful change in federal treatment could influence how these businesses are valued and acquired.
Consider three potential scenarios.
Scenario 1: Broader Schedule III rescheduling is finalized.
Qualifying operators could see improved federal tax treatment, potentially supporting stronger after-tax cash flow, increased investor interest and improved acquisition economics.
Scenario 2: The process remains delayed.
Buyers and sellers continue negotiating against today's regulatory uncertainty. Some transactions may incorporate contingent consideration or other mechanisms that allocate the risk of future changes.
Scenario 3: The broader proposal is rejected or materially modified.
Businesses would need to reassess assumptions based on the actual final regulatory outcome rather than anticipated reform.
None of these outcomes is guaranteed.
And in every scenario, fundamental M&A diligence remains essential.
Buyers still need to understand the target's financial performance, liabilities, licensing, real estate, capital requirements and ability to operate profitably.
Will Schedule III Trigger More Cannabis Industry Consolidation?
We think that is very likely.
Cannabis industry consolidation has already been driven by operating pressure, limited access to capital, changing valuations and the pursuit of scale.
Federal rescheduling could become another factor influencing that process.
Stronger operators may become more active buyers if their cost of capital declines or their after-tax cash flow improves.
Owners considering an exit may reassess valuation expectations.
Investors may revisit acquisitions, recapitalizations and strategic combinations that previously appeared uneconomic.
But an important principle remains:
A regulatory catalyst does not replace business fundamentals.
A poorly performing cannabis business does not automatically become an attractive acquisition because federal rules change.
Likewise, an otherwise attractive business may warrant a strategic transaction before regulatory uncertainty is resolved.
The decision depends on current economics, market position, available capital and the objectives of the owners.
What Should Cannabis Business Owners Do Now?
Our recommendation is straightforward: prepare for multiple outcomes rather than betting the business on a specific federal deadline.
Owners considering a sale, acquisition, refinancing or strategic partnership should understand their current financial position and how different regulatory scenarios could affect it.
That includes evaluating normalized operating performance, tax liabilities, working capital, licensing status, lease obligations, capital expenditures and transaction readiness.
The most valuable preparation is often completed before a regulatory catalyst changes buyer expectations.
For cannabis businesses considering an M&A transaction, the objective should be to establish a defensible valuation based on present performance while identifying potential upside separately.
The opportunity is to be transaction-ready, not merely optimistic about rescheduling.
What's Next for the DEA Rescheduling Hearing?
As of October 14, 2026, the immediate question is procedural.
Judge Julius must resolve the request involving the GAO report and determine whether additional briefing or other proceedings are warranted.
Once the hearing record is complete, the judge can issue a recommendation. The DEA administrator would then make the final agency determination through the applicable rulemaking process, subject to potential further legal challenges.
There is no confirmed final date for broader marijuana rescheduling.
For cannabis owners, the takeaway is clear:
The federal government has already taken a meaningful step toward loosening restrictions on certain medical marijuana products. Broader Schedule III rescheduling remains possible, but the administrative process is not finished.
That distinction matters for tax planning, financing and cannabis M&A.
FAQs
Q: Is marijuana federally Schedule III in 2026?
A: Certain FDA-approved marijuana products and qualifying state-regulated medical marijuana products were placed in Schedule III through an April 2026 rule. Broader marijuana rescheduling remains pending as of October 14, 2026.
Q: Why is the DEA marijuana rescheduling hearing delayed?
A: The administrative law judge paused proceedings while considering whether a GAO report about federal drug-scheduling procedures should be added to the hearing record and whether further arguments are needed.
Q: Does the DEA support marijuana rescheduling?
A: In the current administrative proceeding, the DEA is defending the proposal to transfer marijuana from Schedule I to Schedule III. It has opposed additional briefing concerning the GAO report.
Q: Will Schedule III eliminate Section 280E for cannabis businesses?
A: Section 280E applies to trafficking in Schedule I and II substances. A broader move to Schedule III could remove that restriction for covered activities, but businesses should obtain tax advice about the actual scope, effective date and application of federal rules.
Q: Will cannabis rescheduling increase business valuations?
A: It could improve after-tax cash flow and acquisition economics for qualifying operators, potentially influencing valuations. The effect will depend on the final rules, business performance, financing conditions and buyer demand.
Q: Does Schedule III legalize cannabis nationwide?
A: No. Rescheduling changes federal controlled-substance classification; it does not automatically create unrestricted nationwide cannabis commerce or eliminate state and federal licensing requirements.
Q: What does cannabis rescheduling mean for mergers and acquisitions?
A: Potentially improved tax economics, financing conditions and investor interest could influence acquisition activity. However, cannabis M&A transactions must still be evaluated based on current financial performance, licensing, liabilities, real estate and transaction structure.
The Bottom Line
The DEA's latest response is a constructive development for supporters of broader cannabis rescheduling, but it is not a final decision.
The administrative hearing remains delayed while the judge considers additional procedural requests.
For cannabis business owners and investors, the larger issue is how to prepare for a changing regulatory environment without treating uncertain future benefits as guaranteed.
Regulatory reform may create opportunities. Strategic preparation determines who is positioned to act on them.
Considering a Cannabis Acquisition, Sale or Strategic Transaction?
Pac Garden Assets provides Strategic M&A, Cannabis Business Advisory and Commercial Real Estate services to cannabis owners, operators and investors throughout California.
Whether you're evaluating a sale, acquisition, recapitalization or real estate strategy, we can help assess the commercial considerations and coordinate with appropriate legal, accounting and regulatory professionals.
Connect with Pac Garden: https://www.pacgarden.com/contact
Disclaimer: This article is for educational and informational purposes only and does not constitute legal, tax, investment, securities or financial advice. Federal and state cannabis laws and their application may change. Consult qualified legal and tax professionals regarding specific operations and transactions.
Comments